Insulin Resistance in Women With Prolactinoma
Only registered users can translate articles
Log In/Sign up
The link is saved to the clipboard
StatusCompleted
Sponsors
Universidade Federal do Rio de Janeiro
CLINICAL TRIAL: NCT00481299
BioSeek: nct00481299
Keywords
Abstract
Prolactin is suggested to influence insulin resistance, but scarce data is available on the metabolic profile of patients with prolactinoma.
The purpose of the protocol was to evaluate cardiovascular disease risk factors in women with prolactinoma treated with dopamine agonists and to study the influence of disease control and anthropometry on their metabolic profile.
Description
A cross-sectional study was performed in non-obese premenopausal women with prolactinoma treated with dopamine agonists evaluated regarding glucose, insulin, Homeostasis Model Assessment (HOMA), lipid profile, C reactive protein (CRP), body mass index (BMI), waist circumference, prolactin, estradiol, testosterone, and sex hormone binding globulin (SHBG). They were compared with control women of similar age and BMI distribution.
Dates
| Last Verified: | 03/31/2007 |
| First Submitted: | 05/29/2007 |
| Estimated Enrollment Submitted: | 05/29/2007 |
| First Posted: | 05/31/2007 |
| Last Update Submitted: | 05/29/2007 |
| Last Update Posted: | 05/31/2007 |
| Actual Study Start Date: | 09/30/2004 |
| Estimated Study Completion Date: | 08/31/2006 |
Condition or disease
Prolactinoma
Insulin Resistance
Hyperlipidemia
Phase
-
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | Female |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - Prolactinoma - Female gender - Premenopausal Exclusion Criteria: - Obesity (BMI ≥ 30 kg/m²) - Diabetes mellitus - Hypertension - GH deficiency - Hypothyroidism - Primary hypogonadism - Adrenal insufficiency - Pituitary surgery |
